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Background: Preclinical testing of potential therapies for Duchenne muscular dystrophy (DMD) is conducted
predominantly of the mdx mouse. But lack of a detailed quantitative description of the pathology of this animal
limits our ability to evaluate the effectiveness of putative therapies or their relevance to DMD.
Methods: Accordingly, we have measured the main cellular components of muscle growth and regeneration over
the period of postnatal growth and early pathology in mdx and wild-type (WT) mice; phalloidin binding is used as a
measure of fibre size, myonuclear counts and BrdU labelling as records of myogenic activity.
Results: We confirm a two-phase postnatal growth pattern in WT muscle: first, increase in myonuclear number over
weeks 1 to 3, then expansion of myonuclear domain. Mdx muscle growth lags behind that of WT prior to overt
signs of pathology. Fibres are smaller, with fewer myonuclei and smaller myonuclear domains. Moreover, satellite
cells are more readily detached from mdx than WT muscle fibres. At 3 weeks, mdx muscles enter a phase of florid
myonecrosis, accompanied by concurrent regeneration of an intensity that results in complete replacement of
pre-existing muscle over the succeeding 3 to 4 weeks.
Both WT and mdx muscles attain maximum size by 12 to 14 weeks, mdx muscle fibres being up to 50% larger than
those of WT as they become increasingly branched. Mdx muscle fibres also become hypernucleated, containing
twice as many myonuclei per sarcoplasmic volume, as those of WT, the excess corresponding to the number of
centrally placed myonuclei.
Conclusions: The best-known consequence of lack of dystrophin that is common to DMD and the mdx mouse
is the conspicuous necrosis and regeneration of muscle fibres. We present protocols for measuring this in terms
both of loss of muscle nuclei previously labelled with BrdU and of the intensity of myonuclear labelling with
BrdU administered during the regeneration period. Both measurements can be used to assess the efficacy of
putative antinecrotic agents. We also show that lack of dystrophin is associated with a number of previously
unsuspected abnormalities of muscle fibre structure and function that do not appear to be directly associated
with myonecrosis.
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From shortly after its discovery in the early 1980s [1],
the mdx mouse fell into disrepute and was widely dis-
missed as a model of human muscular dystrophy [2-5];
that its muscles are hypertrophic and of similar absolute
strength to those of the C57Bl/10 wild-type (WT) mouse
did not fit well with the muscle-wasting phenotype of
Duchenne muscular dystrophy (DMD) boys. Its eventual
revelation as a genetic homologue of DMD [6] subse-
quently established it as the most-used preclinical model
of DMD but with the common proviso that the mdx
pathology is much less severe. This comparison is based
mainly on the progression of muscle fibrosis and, im-
portantly, of clinical incapacity expressed as a proportion
of the lifespans of man and mouse, a debatable basis for
comparison of pathological severity between two such
different species [7]. Persistence of such opinions is abet-
ted by a lack of well-authenticated quantitative criteria
in either species by which such comparisons might
validly be made. While current technologies permit us
to gather detailed quantitative information on gene
expression and proteomic profiles in DMD and mdx
dystrophies [8-10], at the level of cellular pathology, we
lack equivalent data to permit accurate translation of
molecular events into pathological processes.
To realize the full potential utility and to accommo-
date the limitations of the mdx mouse as a preclinical
model requires a deeper understanding of its pathology
by comparison with that of DMD in man. A full quanti-
tative description of the processes involved in generating
pathological changes over the course of disease, espe-
cially of the dynamics of those processes, could provide
a basis for determining the role of each pathological
feature of the mdx dystrophy in the development of the
disease. Such information is required to fully evaluate
the applicability, or otherwise, to DMD of data emer-
ging from this animal model and to better interpret re-
sults from tests of potentially therapeutic preclinical
interventions.
To understand those features that are common to the
two species and those that differ between them, we need,
at a minimum, to develop quantitative methods in the
mouse for measuring and comparing the benefits to
pathology and function of any putative therapeutic treat-
ment. At present, we have only a hazy understanding of
the relationship between the pathological targets that we
are aiming to modify with a given treatment and the
outcome criteria that are commonly assessed in such in-
vestigations. For example, variation in fibre size, the fre-
quency of centrally placed myonuclei or the deposition
of fibrous connective tissue are all recognized as conse-
quent to dystrophic pathological processes in the mdx
mouse, but their relationships to the primary pathology
unleashed by the lack of dystrophin are indirect andobscure. Likewise, although the molecular mechanisms
by which putative treatments are thought to modify
these processes are often identified, the cellular mecha-
nisms that translate these molecular changes into struc-
tural and functional improvements remain largely
unresolved. As a first approach to gaining a better
understanding of these various relationships, we have
made a detailed examination of the mdx mouse
muscle during its phase of postnatal growth, driven
by conspicuous satellite cell activity, and of its transi-
tion, at the end of this period, into a florid myopathic
stage that is accompanied by even more intense satel-
lite cell activity.
We have assessed these events by three main methods.
First, we have monitored the accumulation of myonuclei
within muscle fibres as a measure of the contribution of
myogenic cell fusion to fibre growth. Second, the con-
tent of fibrous actin has been measured as an index of
the amount of contractile material within each muscle
fibre. Third, we have followed the incorporation of the
thymidine analogue BrdU into muscle fibre nuclei as a
measure of myogenic activity and loss of these labelled
nuclei as an indicator of myonuclear turnover in the
period of growth and at the onset of myopathology in
mdx mice.
We demonstrate a number of previously unrecognized
consequences of absence of dystrophin from skeletal
muscle. In particular, muscle growth in mdx mice is
markedly compromised prior to the onset of overt
myonecrosis; growth of mdx fibres lags behind that
of WT fibres, with fewer myonuclei that have smaller
sarcoplasmic domains. This hypotrophy is accompan-
ied by feeble attachment of satellite cells to the mdx
fibres but appears to originate pre- or peri-natally.
At 3 weeks, WT muscle growth involving satellite cell
activity ceases, further enlargement being accomplished
by expansion of the myonuclear domain. In contrast,
mdx mice at this age enter a sudden myonecrotic phase
and myogenic activity becomes yet more conspicuous,
coping with both the hypertrophic growth and the re-
pair of extensively destroyed muscle fibres. At maturity,
mdx muscles and their component myofibres are larger
than those of WT and are hypernuclear, with more than
double the number of myonuclei per fibre. Thus, al-
though hypertrophic in terms of absolute bulk, muscles
of the mdx mouse can be considered hypotrophic in
terms of myonuclear domain, which falls to half the
WT value. We propose that the mdx mouse differs
greatly from DMD in having no problem of repair and
regeneration. This brings into question its value as a
model of this aspect of dystrophinopathy. However, the
basic similarity of myonecrotic events commends it as
a model for testing therapies aimed at modifying this
aspect of DMD.
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Animals and BrdU and EdU administration
C57Bl10/ScSn mice and mdx C57Bl10/ScSn mice were
managed and handled according to protocols approved
ethically and scientifically by the local animal care and
use committee guidelines of the Children’s National
Medical Center, Washington, DC. For some experi-
ments, mice were injected subcutaneously with BrdU
(30 mg/kg) morning and evening for the first postnatal
week. Administration of BrdU to post-weaning mice was
by inclusion in their drinking water (0.8 mg/ml) for a
period of 1 week. In some experiments, pre-weaning
mice were injected twice daily with EdU, which is more
easily visualized but too expensive to be administered in
the drinking water and is more toxic than BrdU in lon-
ger term administration protocols.
Mice aged 1, 2, 3, 4, 6, 14 and 28 weeks were eutha-
nased by CO2 flooding followed by cervical dislocation,
and tibialis anterior (TA), gastrocnemius and extensor
digitorum longus (EDL) muscles were dissected from
both hindlimbs.
Isolation of myofibres
Reagents were from Invitrogen (Thermo Fisher Scientific,
Grand Island, NY, USA) unless otherwise stated. Single
myofibres were isolated as described previously [11].
Briefly, right limb EDL muscles were carefully dissected
immediately after euthanasia of the mouse and incubated
in 0.2% Collagenase Type 1 (Sigma-Aldrich, St. Louis,
MO, USA) in DMEM for 1 to 2 h, depending on muscle
size and age, to digest the connective tissue. Single
myofibres were liberated by gentle trituration with fire-
smoothed wide-mouthed Pasteur pipettes in DMEM in
dishes pre-coated with horse serum. Liberated myofi-
bres were washed by transfer through four such dishes.
TA and gastrocnemius muscles of mice that had been
given BrdU were frozen on corks in isopentane held at
freezing point in liquid nitrogen for subsequent cryostat
sectioning.
Immunostaining
EDL muscles from 16-day-old mdx and WT mice (n = 4)
were frozen in liquid-nitrogen-cooled isopentane. Trans-
verse sections cut at −20°C were incubated for 1 h at RT
in permeabilization/blocking buffer (TBS-T, 0.5% Triton
X-100, 2% BSA 2% (w:v), 20% goat serum) and then
overnight at RT in primary antibodies diluted in
permeabilization and blocking buffer. Anti-laminin-2
(clone 4H8-2, 1:400, Axxora, Lausen, Switzerland) was
used to define fibre margins and LAMP1 (dilution 1:300,
H-228, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) to visualize lysosomal structures. Slides were then
washed three times in TBS-T 10 min at RT prior to in-
cubation in secondary antibodies (goat anti-rat AlexaFluor 488, 1:400, Invitrogen; donkey anti-rabbit Alexa
Fluor 595, 1:400, Invitrogen) diluted in permeabilization
and blocking buffer. After three 10-min washes in TBS-T
at RT, the slides were counter-stained with DAPI, 1 μg/ml
for 2 min, rinsed two times and mounted with Gel Mount
(Sigma). Four images of 1-μm-thick optical sections were
gathered from each section, using Zeiss LSM 510 Meta
NLO on an Axiovert 200 M microscope (Carl Zeiss, Jena,
Germany). Images were acquired using AxioVision soft-
ware (Carl Zeiss).
BrdU staining with biotin-conjugated anti-BrdU (Life
Technologies B35138) 1:100 overnight, followed by
Alexa 488 streptavidin (Invitrogen S32354) 1:500, was
performed according to the supplier’s instructions.
Laminin co-staining was performed by overnight incuba-
tion at 4°C with anti-laminin antibody (Sigma L9393)
1:400, followed by Marina Blue goat-anti-rabbit IgG
(Invitrogen M10992) 1:500 for 1 h at RT to reveal the
primary antibody localization.
EdU-treated mice were euthanased on postnatal day
18 and EDL muscles were harvested. Single myofibres
were isolated as described above. EdU detection was per-
formed on fixed myofibres using the Click-iT Assay kit
(Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions. DAPI was used to visualize
nuclei.
Isolation, immunostaining and counting of Pax7-positive
cells
Myofibres were isolated as described above, fixed with
4% paraformaldehyde and immunostained with anti-
Pax7 antibody (Developmental Studies Hybridoma Bank,
Iowa City, IA, USA) as previously described [12].
Fixation and phalloidin staining of myofibres
Batches of myofibres harvested at each age were trans-
ferred to a 2-ml Eppendorf vial containing 1.5 ml 3.65%
formaldehyde and fixed at 37°C for 15 min. The vial was
centrifuged at 700 g for 10 min, to loosely pellet the
myofibres. The formaldehyde supernatant was carefully
removed, and 1 ml of 30% sucrose was added to the pel-
let which was resuspended by a 3-s vortex and stored
at −80°C pending analysis.
For staining, the vials were thawed at room tem-
perature and the contents deposited into a Petri dish
together with the products of a rinse with TBS-
Tween (Tween 0.1% in TBS). Using a stereo micro-
scope and watchmaker’s forceps, myofibres were
carefully transferred into a 2-ml Eppendorf vial con-
taining permeabilization and blocking buffer (0.5%
Triton, 0.1% Tween, 2% BSA and 20% goat serum) in
which they were incubated overnight at 4°C. After
centrifugation for 10 min at 15,000 g, the buffer was
removed and the fibres were rinsed three times with
Figure 1 Plot of fluorescent phalloidin signal per myonucleus
against estimates of fibre volume per myonucleus from stacked
confocal images visualized in segments of muscle fibres isolated
from mdx and WT muscles at ages of 2, 6 and 28 weeks. The strong
linear relationship between the two parameters across the age
range and the two mouse strains validates the use of phalloidin
fluorescence as a reliable index of fibre volume within these limits.
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(0.1% Tween in TBS).
The myofibres were then re-suspended in Alexa Fluor
594-conjugated phalloidin at a dilution of 1:40 for
20 min at room temperature, as previously described
[11], rinsed three times and left in the rinse solution
overnight at 4°C to maximize elution of unbound phal-
loidin. After centrifugation for 10 min at 15,000 g, myofi-
bres were re-suspended in a 0.75 μg/ml solution of
DAPI and immediately centrifuged for a further 10 min
at 15,000 g, then rinsed once more. The contents of the
vial were deposited into a Petri dish and transferred gen-
tly, using a stereo microscope and forceps, and mounted
onto a microscope slide.
Imaging and software analysis
Single fibre imaging and quantification of F-actin was
performed as previously described [11]. Briefly, stained
myofibres were imaged on a Nikon Eclipse E500 epi-
fluorescence microscope with Spot Camera (Nikon
Corporation, Chiyoda-ku, Japan). Overlapping seg-
ments of each myofibre were recorded under a Nikon
PlanApo × 10 objective. Between two to six images were
required, depending on the length of the myofibre.
Exposure time was set to fall within a previously val-
idated linear response range of signal intensities [11]
and was kept constant across all samples within a
comparison. Images of each myofibre were stitched
together using the CS2 version ‘Interactive Layout’
mode of the Photomerge feature of Adobe Photoshop in
Adobe Photoshop Elements.
For measurement of volume, confocal microscopy
z-stacks were acquired on a Zeiss LSM 510 Meta
NLO system with an Axiovert 200 M microscope.
Depths ranged from 35.3 to 61.8 μm, depending on
myofibre thickness. Slices of 2.2 μm thick composed
of 512 × 512 pixels were collected with × 20 objective.
Between two to six non-adjacent z-stacks were col-
lected per myofibre, depending on myofibre length.
DAPI-stained nuclei were counted for each z-stack
by eye from three-dimensional representation using
AxioVision software (Zeiss) and added together. Volume
data of each segment are expressed per myonucleus within
that segment.
Integrated density of signal from fluorophore-
conjugated phalloidin for each slice was calculated
in ImageJ and added together to give total signal per
z-stack. Signals per z-stack were added for each myo-
fibre and divided by the number of nuclei to give
signal per nucleus.
Measurement of growth of muscle fibres
To follow growth of muscle fibres from WT and mdx
mice, we recorded the two main contributory factors:the numbers of nuclei within the muscle fibre (myonuclei)
and the amount of filamentous actin (F-actin). Since most
fibrous actin within the fibre is associated with the myofi-
brillar structures, this is an index of the amount of con-
tractile apparatus. These methods were developed and
analysed for consistency and reproducibility in a previous
study [11]. EDL muscles were dissected from WT and
mdx mice aged from 1 to 28 weeks of age (three animals
per time point) and dissociated in type 1 collagenase as
described above. Batches of fibres obtained from mdx and
WT mice were thawed in age-matched pairs, subjected
to the staining regime, and mounted for microscopic
examination.
Validation of fluorescent phalloidin signal as an index
of volume
To determine the relationship between fibrous actin
content and sarcoplasmic volume, we compared the
phalloidin signal from segments of individual muscle
fibres extracted from EDL muscle fibres of 2-, 6- and
28-week mdx and WT mice with the calculated volumes
of the same segments from z-stacks of confocal images
as described previously [11]. These two measures were
normalized to the number of myonuclei in these same
segments and plotted against one another (Figure 1).
The strong correlation between these two parameters
across the two strains and spanning the entire age range
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reliable index of sarcoplasmic volume within these
bounds, irrespective of age or strain. Thus, we apply the
term ‘myonuclear domain’ as a descriptor of both the
amount of contractile material associated with each
myonucleus as measured by the fluorescent phalloidin
signal and the volume of sarcoplasm calculated from the
regression relationship.
Statistics
For myofibres processed by the PhAct method on a
standard fluorescent microscope, statistical tests for sig-
nificant differences between WT and mdx myofibres in
terms of nuclear counts (myonuclei, peripheral, central-
ized or Pax7-positive) and actin signal (per fibre or nor-
malized to the number of myonuclei) were analysed
within an ANOVA framework. Some parameters were
transformed to achieve normal distributions (square-
root transformation: Pax7-positive nuclei per total nuclei
and actin signal; log transformation: actin signal per
myonucleus, total nuclei and myonuclei), then two-way
ANOVA was performed for each age. Factors included
into the model were the murine strain and the experi-
mental batch of the myofibres.
For myofibres imaged using confocal microscopy, for
which volume per nucleus and actin per volume were
measured, because of the non-normality of dependent
variables, non-parametric tests were used to compare
medians. For the analysis at each time point, the
Wilcoxon rank-sum test was used to compare strains.
Results
Postnatal fibre growth differs substantially between mdx
and WT muscle fibres
Simple visual comparison of age-matched isolated fibre
preparations from WT and mdx muscles indicated that
for the first 4 weeks, mdx fibres tended to be smaller
but, beyond 6 weeks, appeared larger than those of WT
and showed branching that was not observed in those of
WT (Figure 2). To quantify myofibre growth, we ana-
lysed myofibres isolated from WT and mdx mice by two
main criteria: the number of myonuclei and the amount
of fibrous actin they contained as plotted in Figure 3A,B.
These data confirmed the visual impression that mdx
myofibres lagged behind those of WT in both respects
for the first 4 postnatal weeks but overtook them in
terms of absolute size (phalloidin fluorescent yield) in
mature animals.
Myofibre growth in WT mice
As expected from previous studies [13], myonuclear
number per WT fibre increased steadily over the first
3 weeks, when it ceased abruptly (Figure 3A). All further
growth occurred by increase in the amount of F-actinper fibre, as indicated by the progressive rise along the
Y-axis of the individual data points in Figure 3A, without
further increase along the X-axis. The increasing slope
of the correlation lines within the WT fibre population
also indicates an increase in the F-actin (that is, sarco-
plasmic volume) per myonucleus up to 14 weeks of age,
with no further increase by 28 weeks.
Growing mdx muscle is hypotrophic prior to the onset
of disease
For the first 3 to 4 weeks, muscle fibres of mdx mice
followed a largely similar pattern of increase in myonuc-
lear number per fibre accompanied by a small increase
in fibrous actin content (Figure 3B). But, thereafter, the
myonuclear number per mdx fibre increased progres-
sively along the X-axis to more than twice that seen in
WT muscles of equivalent age. The F-actin content also
increased to higher average levels than that of WT but
were highly variable and not in proportion to myonuc-
lear number.
The difference between patterns of myogenesis in WT
and mdx mice is depicted more succinctly as plots of
the average fluorescent phalloidin signal per muscle fibre
(Figure 4A) and per myonucleus (Figure 4B) across the
range of ages.
In WT myofibres, the fluorescent signals per myofibre
and per myonucleus both increase continuously up to
14 weeks of age, where they stabilize.
In mdx myofibres, by contrast, both relationships are
biphasic, following two distinct courses. Up to the onset
of frank myonecrotic disease at 3 to 4 weeks, the
fluorescent phalloidin signal, both per myofibre and per
myonucleus, lags significantly behind that of the age-
matched WT. This confirms the visual impression in
Figure 2 that individual mdx fibres are smaller in these
young mice (Figure 4A). Calculation of the myonuclear
domain from the fluorescent phalloidin yield (Figure 4C)
confirms that this too is significantly smaller in mdx
than in WT fibres in these young growing muscles as
well as later in the adult mice.
Hypotrophic growing mdx muscle fibres contain fewer
myonuclei than WT fibres
Up to week 4, fewer myonuclei were routinely seen in
mdx than in the age-matched WT myofibres but not sig-
nificantly so at any given time point. We therefore con-
ducted a larger experiment to determine whether the
difference was real and whether myogenic activity was
lower in mdx mice during this postnatal growth period.
Three WT and three mdx mice were each injected twice
per day with EdU (0.5 mg/g) from p13 to p15, prior
to euthanasia at 18 days. Analysis of ten isolated
EDL fibres per mouse showed that mdx myofibres
contained significantly fewer myonuclei than age-matched
Figure 2 Individual fibres isolated from muscles of mdx and WT mice aged from 1 to 28 weeks. The visual impression that muscle fibres of mdx
mice are thinner than those of age-matched WT controls is borne out by analyses shown in subsequent figures. Branching is evident in the older
mdx fibres.
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by a 3-day administration of EdU over this period,
which would comprise both myogenic cells in mitosis
over the labelling period and myonuclei derived from
them, did not differ significantly between WT and
mdx (Figure 4E).
We conclude that for the first 3 to 4 postnatal weeks,
mdx muscle fibres are hypotrophic, in terms of all
parameters we have measured; that is, they are of signifi-
cantly smaller volume and contain significantly fewermyonuclei with significantly smaller sarcoplasmic do-
mains than the age-matched WT fibres.
Detailed plots of the myonuclear numbers in fibres
over weeks 1 to 4 (Figure 4F) confirm that the lower
myonuclear numbers in mdx myofibres are not attribut-
able to differences in rate of proliferation of myogenic
cells. They show that the accumulation of myonuclei in
mdx and WT fibres rose in parallel over this growth
period but with the mdx lagging slightly behind the WT;
both showed an increase of 100 myonuclei per fibre
Figure 3 Growth of mdx and WT muscle fibres up to 28 weeks of age, showing the total phalloidin fluorescence per myofibre, as an indicator of
fibre volume, plotted against the number of myonuclei in that myofibre, displayed as individual data points and linear best fits across the range
of ages as identified by colour. (A) Growth of WT fibres. Myonuclear number, plotted along the X-axis, increases up to week 3 but not thereafter,
all further growth being accomplished by increase in fibrous actin content, along the Y-axis, as indicated too by the increasing slope of the best
fit lines. (B) The equivalent plot to (A) of mdx muscle fibres using the same scales, to show the marked difference between growth patterns of
the two strains. Up to week 4, mdx growth is broadly similar to that of WT but, beyond this point, continues both by a great increase in number
of myonuclei per fibre and by increase in F-actin content. The total F-actin per fibre becomes larger than that of WT, in association with fibre
branching, but the ratio of fibrous actin per myonucleus is low, as indicated by the shallow slopes of the best fit lines.
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60/75 myonuclei per fibre by week 3 and further, to ap-
proximately 45 when averaged over the first 4 weeks.
We conclude that lack of myonuclei over the postnatal
growth period does not reflect a lower rate of myogenic
cell proliferation and fusion during this time and that it
must have arisen at or before birth.In the context of continuously degenerating/regenerating
muscle beyond week 3, the low F-actin content per
myonucleus is unsurprising [14] but the seeming lag
in growth of this factor prior to this time was unex-
pected. The small myonuclear domain in these young
mdx is not attributable, as it is during the subse-
quent myopathic stage, to excessive myonuclear numbers
Figure 4 Difference between patterns of myogenesis in WT and mdx mice. (A) Fluorescent phalloidin signal per myofibre (mean ± SEM)
plotted against age, illustrating the lag in mdx fibre growth in up to 6 weeks but progressive hypertrophy beyond this point (*P < 0.05).
(B) The fluorescent phalloidin signal per nucleus (mean ± SEM) also increases rapidly in both mouse strains up to 6 weeks, but with mdx
lagging significantly (*P < 0.05) behind WT. The subsequent continuing rise in WT fibres contrasts with the fall to half of the WT values in
mdx. (C) Column plot of the estimated myonuclear domains in muscle fibres isolated from muscles of 2-, 6- and 28-week WT and mdx mice
(mean ± SEM, *P < 0.05). (D) Scatterplots, together with depiction of mean ± SD, of myonuclear number per myofibre isolated from 18-day-old
WT and mdx mouse EDL muscles. (E) EDL fibres from mice labelled with EdU at 14, 15 and 16 days of age and analysed on day 18 showing
similar labelling frequencies of fibre-associated nuclei (new-formed myonuclei plus Pax7-positive satellite cells). (F) Nuclear number/fibre
(mean ± SD) of fibres isolated from muscles of mdx and WT mice at weeks 1 to 4. The successive incremental plots show a progressive fall in
slope from 100 nuclei/fibre between weeks 1 and 2 to a net rise of approximately 45 nuclei per fibre averaged across weeks 1 to 4. Cessation of
WT growth is evident beyond week 3. Myonuclei numbers in mdx fibres fall consistently below those of WT fibres, but the plots run largely
parallel suggesting that the intensity of myogenesis in the two strains is closely similar and that the mdx fibres had fallen behind WT during
prenatal development.
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sarcoplasmic protein per myonucleus during this growth
phase.
Thus, the postnatal hypotrophy of mdx EDL muscle
arises from two factors: a smaller myonuclear domain in
combination with fewer myonuclei per fibre than WT.
In previous tissue culture studies, we had observed a
similar hypotrophic pattern to that seen here in vivo,
that is, hyponucleated myofibres in the context of
equivalent overall myogenicity and small myonuclear do-
main; this in association with elevated lysosomal content
as well as with excess secretion of protein in lysosomal
vesicles [15]. As shown in Figure 5A, the hypotrophic
mdx fibres in pre-necrotic mdx muscle in vivo are alsoFigure 5 Mdx muscles show excess lysosomal activity prior to disease and
2-week-old mdx and WT muscles immunostained for laminin (red) to show
representation of lysosomes within mdx fibres as a possible contributory fa
BrdU (green) and laminin (red) counter-stained with propidium iodide (red
during the first week of life and euthanased at 16 or 42 days of age. At 16
showed similar frequencies of labelled nuclei. N = 4 muscles. Data are show
at 42-day muscle, both by identifiable myonuclei (arrowed) and by interstit
whole section) centrally placed labelled myonucleus in the mdx muscles.heavily loaded with lysosomes, suggesting that similar
aberrations of protein handling and secretion may con-
tribute to the hypotrophic status of these fibres.
Onset of myopathy in mdx mice involves a switch from
hypotrophy to a hyperplasia-driven hypertrophy
Beyond 3 to 4 weeks of age, the phalloidin signal per
mdx myofibre increases more rapidly than WT with age.
This reflects an increase to a very large size of mature
mdx myofibres (Figures 3B and 4A) accompanied, at 14
and 28 weeks, by an even greater increase in myonuclear
number with the result that sarcoplasmic volume per
myonucleus, that is the myonuclear domain, was reduced
to half of that of WT fibres at these ages (Figure 4B,C).massive turnover after onset. (A) Cryostat sections of TA muscles from
fibre outlines and Lamp1 (green) and DAPI (blue) to show the strong
ctor to the hypotrophic condition of these fibres. (B) Immunostains for
) of the section of TA muscles from mice injected twice daily with BrdU
days, prior to the onset of myonecrosis, muscle from both strains
n as mean ± SD. In the WT muscle, the BrdU label had been retained
ial cells but had been lost, apart from the occasional rare (1 to 2 per
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muscle fibres
To examine the dynamics of the initial growth and tran-
sition from growth into disease, we injected a cohort
each of newborn mdx and WT mice with BrdU subcuta-
neously twice per day (morning and evening) on postna-
tal days 1 to 7. At 16 days of age, counts of labelled
muscle fibre nuclei per unit area of muscle from mdx
and WT mice (Figure 5B, n = 4 mice) showed no differ-
ence between the two strains, adding to the preceding
evidence that the lower myonuclear content in mdx
compared to that in WT muscle fibres over the first
3 weeks is not attributable to diminished myoblast pro-
liferation during this period.
By 42 days of age, muscle sections from four mice
from each of these same labelled cohorts showed a stark
divergence between the two strains in retention of la-
belled nuclei. In WT muscles, numerous BrdU-labelled
nuclei were identified both in myonuclear positions
within the myofibres and in the interstitium between
fibres. By contrast, in mdx muscles at this age, only a
very rare isolated labelled nucleus per whole muscle sec-
tion was found in either position. Since myonuclei do
not divide, loss of labelled myonuclei from mdx muscle
must reflect loss of the nuclei themselves, presumably
associated with death and replacement of the fibre, ra-
ther than by the main alternative, namely, mitotic dilu-
tion of the BrdU label to subliminal levels. For the
interstitial nuclei, either explanation is possible. Overall,
the loss of BrdU-stained myonuclei indicates that the
majority of muscle fibres had been lost and replaced
over the 3 weeks between the onset of the myopathy
and time of examination. Thus, muscle precursor cell
activity over this 3- to 6-week period had not only re-
placed the complete muscle mass but, as shown expli-
citly in Figure 3B and by implication from the halving of
the myonuclear domain in Figure 4B,C, had augmented
the total myonuclear content by approximately 100%
over the number in the WT mouse.
The changing relationship between satellite cells and
muscle fibres during postnatal growth and regeneration
in mdx muscles
Counts of Pax7-positive satellite cells on WT fibres over
the first 3 weeks corresponded well to those found by
White et al. [13], but muscle fibres isolated from mdx
muscles carried far fewer of these cells than their age-
matched WT equivalents (Figure 6A,B). This reconciles
poorly with the similar rates of incorporation of new
myonuclei into growing fibres of the two strains over
this period (Figure 4F) or the similar frequencies of in-
corporation of EdU and BrdU labels into nuclei during
postnatal weeks 1 to 3 (Figures 4E and 5B). Suspecting
that satellite cells were being lost preferentially fromthese young mdx muscle fibres during the isolation
process, we counted Pax7-positive cells, per fibre profile,
in cryostat sections of EDL muscles at 14 days of age
and found no significant difference between mdx and
WT muscles (Figure 6C). Thus, Pax7-positive cells were
present with equal frequency in situ in these young mdx
and WT EDL muscles but were lost preferentially from
mdx fibres during the isolation procedure, suggesting
that their adhesiveness to these young growing fibres
was reduced in the absence of dystrophin.
By 6 weeks of age, mdx muscle fibres carried equiva-
lent numbers of satellite cells to those of WT muscle fi-
bres and the frequencies of satellite cells per mdx fibre
rose consistently over the remaining period of observa-
tion to higher numbers than those of satellite cells per
WT fibre (Figure 6A). Interestingly, the satellite cell
number standardized to myonuclear number per fibre
was constant over the entire period from 6 to 28 weeks
(Figure 6B). Maintenance of so similar a proportionality
in such dissimilar conditions as the WT and mdx
muscles implies some hitherto unremarked interaction
between the myonuclear population and satellite cell
number.
Fibre splitting increases progressively with age in
mdx muscle
Beyond 6 weeks of age, we show a significant increase in
mdx myofibre volume, as indicated by fluorescent phal-
loidin signal, that is not proportionate to the more than
doubling of myonuclei. The reported hypertrophy of
mdx mouse muscles is not matched by increased fibre
diameter [16] but, as shown in Figures 2, 6D and 7A, is
accompanied by a progressive increase in the frequency
of branched or split fibres [17-19], which has recently
been shown to play a major role in mdx muscle hyper-
trophy [19].
‘Central’ nuclei account for the myonuclear excess in mdx
over WT
A noted feature of mdx mouse muscle and of regener-
ated muscle in the adult mouse in general [20] is the
large proportion of nuclei distributed in centrally placed
strings [20,21] (Figure 7A). In our counts, we designate
myonuclei in aligned strings as ‘central nuclei’ (that is,
not in the normal juxta-sarcolemmal position) in distinc-
tion from those not in this configuration which we clas-
sify as peripheral myonuclei. In this investigation, we
find no central strings of nuclei in the WT fibres at any
age. In mdx fibres, they are first seen at 6 weeks of age
and increase rapidly by 14 and 28 weeks. Counts reveal
that these ‘central’ myonuclei account fully for the
higher total myonuclear number in mdx muscle fibres
(Figure 7B). In fact, the numbers of myonuclei lo-
cated peripherally in the regenerated myofibres remain
Figure 6 Numbers of Pax7-positive satellite cells and of fibre branches in mdx and WT muscles. (A) Numbers of satellite cells on myofibres
extracted from EDL muscles of 1- to 28-week-old WT and mdx mice, shown as Pax7-positive cells per fibre (mean ± SEM). Up to week 4,
mdx fibres carried markedly fewer satellite cells than those of WT. Beyond 6 weeks of age, the numbers of satellite cells on mdx fibres
increased progressively and significantly exceeded the WT number at 14 and 28 weeks.(B) Pax7-positive cells on fibres extracted from EDL
muscles of 1- to 28-week-old WT and mdx mice, normalized to total myofibre nuclei (mean ± SEM). Again, during the first 4 weeks, the
percentage of satellite cells on mdx fibres is markedly lower than that on WT fibres but, at 6 weeks and beyond, the numbers are closely
similar, suggesting a link between myonuclear density and satellite cell number in mature muscle. (C) Numbers of Pax7-positive cells per
myofibre profile in frozen sections of muscle from 2-week-old mdx and WT mice (three individual mice of each strain). In the sectioned
muscle, Pax7-positive cells are equally frequent in WT and mdx mice at this age. (D) Frequency of fibres bearing one to four branches in
muscles of mdx mice at 6, 14 and 28 weeks of age. No branches were seen on fibres extracted from three batches of mdx mice younger
than 6 weeks or from WT mice at any age examined, but the frequency and complexity of branching increased progressively with age of
the mdx mouse.
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and do not differ significantly from the numbers of total
myonuclei per fibre in age-matched WT muscles. Al-
though the supernumerary myonuclei in older mdx
muscle correspond numerically to the central nuclei,
myonuclei in both positions are marked by 1 week of
BrdU labelling and we are unable, at present, to
identify either with any specific aspect of the regen-
erative process.
Phasing of muscle growth and regeneration is not limited
to the EDL
Our picture of a cessation of satellite cell-based growth
of WT muscle at 3 weeks of age is based on investigationof fibres from the EDL muscle. To determine whether
this was more broadly true, we gave BrdU to mice in
their drinking water from weeks 4 to 5, looking for signs
of continuing proliferation of myogenic cells in a range
of muscles. As outlined in Figure 8A, mice were eutha-
nased after a further week on water not laced with BrdU
to give any myogenic cells labelled during week 4 ample
time to differentiate and enter a growing or regenerating
muscle fibre. Gastrocnemius and TA muscles of mdx
mice subjected to this protocol showed conspicuous la-
belling of a significant proportion of myonuclei within
focal areas of regeneration, in which virtually all myo-
nuclei were labelled with BrdU (Figure 8B), reflecting
synchrony of regeneration within such spontaneous
Figure 7 Increase with age in the proportion of ‘central nuclei’
and of fibre branching in mdx mice. (A) Interference contrast and
fluorescent micrographs of single fibres isolated from 1-year-old
mdx and WT mice and immunostained for Pax7. These not only
bear readily identifiable satellite cells (green) but also illustrate
the extensive branching of fibres in older mdx but not in WT
mice together with the tendency for myonuclei to be arranged in
linear ‘central strings’. (B) Counts of myonuclei classified into
peripheral location and ‘central’ location, the latter being classified on
the basis of their distribution in linear arrays. These ‘central’ myonuclei
are first seen in 6-week-old mdx mice. At 14 and 28 weeks, however, it
is notable that the numbers of peripherally located myonuclei per fibre
are not substantially different from those of the WT and that the
centrally located nuclei account for all of the excess myonuclei
found in older mdx muscles.
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genic cells had not diluted the label to subliminal
levels within this protocol. Muscles of WT mice sub-
jected to this same regimen showed only occasional
BrdU labelling of interstitial cells and no labelling of
myonuclei (Figure 8C).
Discussion
It is of practical concern that, although the mdx mouse
has been the animal model of first resort for preclinicaltesting of potential therapeutic ideas and agents for
treatment of DMD, we lack a coherent pathological
picture of it. The common assertion that the mdx
dystrophy is milder than DMD remains unsupported
by quantitative data in either species [7]. Here, we
have gathered detailed quantitative information out-
lining the main features that distinguish the mdx
mouse from the WT mouse during its postnatal
growth and the transition to severe pathology. Al-
though comparison with DMD is constrained by the
scanty human data, we do identify several similarities
and differences between mdx and WT that would in-
vite further investigation in man as well as highlight-
ing a number of features of dystrophinopathy that
are not apparent from more casual observation of ei-
ther species.
Of practical interest, we delineate a set of readily
measurable criteria for use in assessment of the bene-
ficial effects of putative therapeutic strategies. We also
identify several features that make this animal less
than ideal, sometimes misleading, as a model of
DMD. Recognition of such issues is important if we
are to avoid developing therapeutic strategies based
on misconception.
Hypotrophy in growing mdx muscles
This is the first report of a lag in growth of mdx EDL
muscle fibres behind that of WT during the early post-
natal growth period. It is a hypotrophy; small fibre size
arises from a combination of fewer myonuclei, each with
a smaller myonuclear domain. We dismiss the idea that
lower myonuclear numbers in isolated mdx fibres during
this period are attributable to the low numbers of satel-
lite cells, since this is revealed as an artefact by the com-
parable satellite cell frequency at 2 weeks in histological
sections of mdx and WT muscles (Figure 6C). This be-
speaks excess satellite cell loss during fibre isolation
from young mdx compared with WT mice, implying a
looser association of satellite cells with mdx than with
WT fibres that might itself predispose to slower growth.
But other evidence argues against this. Even at week 1,
mdx fibres contained fewer myonuclei than WT fibres,
while the actual rate of growth across the 3 weeks was
indistinguishable between the two (Figure 4F), as
were the rates of incorporation of EdU (Figure 4E)
and BrdU (Figure 5B). These data converge on the
idea that the difference had arisen at or before birth
and merely persisted over the postnatal myogenic
growth period. A reported paucity of Pax7-positive
cells in early development in the mdx mouse [22] might
be held responsible for this, but the need for sequestra-
tion of satellite cells beneath the basement membrane
during late prenatal growth [23] provides an alternative
mechanism potentially susceptible to disturbance of the
Figure 8 Assessment of myogenic activity in muscles of mdx and WT mice. (A) Protocol for labelling cell participation in muscle regeneration.
Mice are given drinking water containing 0.8 mg/ml BrdU for 7 days and maintained on normal drinking water for a further 7 days before being
euthanased for analysis. (B) Section from a gastrocnemius muscle taken from a mdx mouse subjected to the regime in (A). Seven days after the
end of BrdU administration, it shows extensive labelling of both interstitial cells and centrally located myonuclei in a spontaneous mdx muscle
lesion (green or yellow). Virtually all of the centrally placed myonuclei are labelled, showing that the BrdU had not been diluted to subliminal
levels by proliferation of the myogenic cells that had repaired this particular lesion. (C) Gastrocnemius of a WT mouse subjected to this same
labelling regimen. An occasional interstitial nucleus is stained, but there are no centrally placed myonuclei and no identifiable myonucleus is
stained. Thus, the cessation of myonuclear-based growth at 3 weeks, identified in the isolated fibres of the WT EDL muscles, is a generalized
phenomenon extending to the gastrocnemius muscle and to other limb muscles examined.
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brane and the fibre plasmalemma [24]. A hangover of
this disturbance would also account for the excessive loss
of satellite cells during isolation of fibres from mdx
muscle during early postnatal growth [25].
The features of pre-myonecrotic mdx muscle fibres
paint a picture of a more complex role of dystrophin in
muscle fibre function than simply sustaining resilience
of the surface. Thus, the mechanisms that bind satellite
cells tightly to the fibre surface are defective, and the
small mdx fibre size is associated with a small myonuc-
lear domain. Both accord well with our previous in vitro
studies where mdx myotubes were atrophic, hyponuc-
lear, highly enriched in lysosomal structures and chron-
ically exported large amounts of intact protein in
aberrant lysosomal vesicles [15]. We show here that this
is reflected in vivo by hypotrophy and excess lysosomal
content of pre-necrotic muscle fibres (Figure 5A). Taken
together, these data portray a broad and pervasive de-
rangement of the metabolic and protein degradation
processes, which precede myonecrosis [25-27], as inte-
gral features of dystrophinopathy.The early phase of the mdx mouse myopathy is severe
We show that myonuclei labelled during the first post-
natal week are largely lost by 7 weeks, 3 to 4 weeks after
the onset of the myopathy (Figure 5B). This indicates
massive myonecrosis and regenerative replacement, as
echoed in the heavy BrdU labelling of myonuclei during
weeks 4 to 5 in newly regenerated foci within all muscles
examined (Figure 8B). Thus, the lag in growth in mdx
muscle up to week 4 is fully compensated by week 6 by
active myofibre regeneration (Figure 4A), even in the
face of massive contemporaneous myonecrosis; this find-
ing fits badly with the idea of distinct and separate
phases of early myonecrosis followed subsequently by
repair [28].
Overall, these findings argue against attribution of the
mild clinical deficiency in mdx mouse to a less aggres-
sive primary pathology than DMD. Indeed, far from
being milder than DMD, it is doubtful whether the in-
tensity of myonecrosis seen in 4- to 6-week mdx mice
would be survivable by a DMD boy. Instead, our data
show that the mdx mouse endures severe early myone-
crotic pathology but is better able than man to cope with
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erative response, as epitomized in Figure 8B. Differences
in scale between mouse and man may play some part in
this [7], but a more fundamental distinction between the
mdx and DMD pathologies is the different timing of the
phases of growth and regeneration in the two species.
Satellite cell-dependent growth in the mouse ceases at
3 weeks, coincident with the onset of myonecrosis and
regeneration, with no overlap between the separate pro-
grammes followed by satellite cells undertaking these
two activities [29]. By contrast, in growing boys, myo-
genic cell proliferation continues throughout the ju-
venile and pubertal periods [30,31], presenting every
prospect of adverse interference in DMD boys between
the separate growth and regeneration programmes.
Thus, some benefit might be achieved by blockade of
discrepant signals between these two different satellite
cell functions.
Quantitative evaluation of disease severity
One objective of this investigation was to develop robust
quantifiable criteria by which to evaluate the severity of
the mdx myopathy and any benefits of putative therap-
ies. Because the spontaneous mdx lesions are focal,
episodic and fleeting [32], there is considerable experi-
mental noise between individual small samples such as
histological sections, so we have broadened the sample
space by adoption of two strategies based on labelling
proliferating 1-week cohorts with BrdU.
1. Twice-daily injection of BrdU for the first postnatal
week labels a neonatal cohort of muscle nuclei
whose loss provides a dramatic signal against which
to test any therapeutic agent. However, the intensive
administration is difficult to standardize and the
rapidity of loss of this labelled cohort limits the
period of testing of therapeutic actions to the initial
myopathic period.
2. We therefore favour the simpler and readily
standardized protocol depicted in Figure 8A,
whereby BrdU is added to the drinking water for
1 week to deliver a chronic supply of the label to the
cohort of cells proliferating during that week, giving
any labelled cells that are destined to participate
in myogenesis ample time to do so during the
subsequent BrdU-free week. As seen in Figure 8B,
virtually every identifiable myonucleus is labelled by
BrdU in regions of intense regeneration triggered by
the spontaneous focal myopathy. Thus, this protocol
fully samples events where myogenic proliferation falls
completely within the week of BrdU administration as
well as partially sampling those that overlap this week.
It also shows that the serial cell divisions within any
single regenerative event do not dilute the label tobelow its subliminal threshold. We can thus measure
the number and size of focal lesions occurring within
a given week and the intensity of labelling within each
lesion. In our hands, this regimen labels myonuclei in
the mdx mouse up to at least 18 months of age
and is currently being used to compare regeneration
across the mdx mouse lifespan and to investigate
the effectiveness of exon-skipping treatments in
suppressing the mdx myopathy.
Muscle hypertrophy and hyperplasia of myogenic cells
Muscle hypertrophy is an ill-understood feature of dys-
trophinopathies [33]. Calf muscle hypertrophy is pathog-
nomonic of DMD, although the gradual replacement of
muscle with fibro-fatty tissue converts this to ‘pseudohy-
pertrophy’ in older boys [34]. In the GRMD dog, the
gluteus, cranial sartorius and tongue show conspicuous
hypertrophy [35,36], and in the mdx mouse, many mus-
cles are routinely heavier than the equivalent WT [37].
Here, we make new observations pertinent to the role of
myogenic proliferation in the hypertrophy.
It remains an enigma that, despite conspicuous myo-
necrosis, muscle of the mdx actually increases in weight
beyond 3 to 4 weeks more rapidly than that of the WT
and maintains normal levels of absolute strength
[14,38,39]. With the possible exception of the dia-
phragm, there is little evidence that diminished regener-
ation plays any significant part in the histopathological
or physiological decline of mdx muscle. Here, we show
that hypertrophic regenerated mdx muscle fibres are
hypernuclear, with double the number of myonuclei per
unit volume so that the adult mdx mouse, as a whole,
contains more than twice as many myonuclei as the WT
mouse. This small myonuclear domain features in the
hypotrophy in growing pre-myopathic mdx and dimin-
ishes further after the onset of myonecrosis and regener-
ation but is more than counter-balanced by the large
numbers of myonuclei per fibre. Thus, the myogenic
mechanisms in the mdx mouse are fully competent to
maintain muscle mass, even in the context of massive
persistent myofibre degeneration, and must entail exten-
sive hyperplasia of the myogenic precursor pool. In ac-
cord with the finding of intact satellite cell number and
function in old mdx mice [40], we have observed occa-
sional BrdU labelling of mdx muscle up to 18 months
(unpublished data). Reports of diminished satellite func-
tion with age in the mdx mouse (for example [17]) may
be attributable to differences between in vitro and
in vivo functional criteria [41,42]. Such exuberant myo-
genic activity in mdx muscle brings into question the
utility of boosting myogenesis in this model [43,44]; it
would be superfluous to the pathological and physio-
logical demands on the muscle, which are accommo-
dated adequately by the existing mechanisms.
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Beyond the first 4 weeks, satellite cell numbers on WT
myofibres remain stable, while, in mdx muscle, the num-
ber per fibre rises steeply, as has been noted previously
[17]. However, if normalized to myonuclear number, the
satellite cell population remains stable at the approxi-
mately 2% level reported for sectioned mouse hindlimb
muscles [45] and indistinguishable between mdx and
WT muscles beyond the 3-week postnatal growth
period. Regulation of satellite cell number has been
viewed largely in terms of intrinsic, cell lineage-defined,
satellite cell qualities that bias the proportion of sym-
metric versus asymmetric divisions, as influenced by
spatial relationships to the basement membrane [46-50].
Our finding that satellite cell number is strongly related
to myonuclear number in both WT and mdx muscles,
even in the context of the abnormal numbers and spatial
distributions of myonuclei seen in adult mdx muscle,
suggests that feedback from the myonuclear population
may also impinge on this important issue.
In DMD, the picture is clouded by uncertainty. At-
tempts to extract and culture myogenic cells have gener-
ally concluded that DMD myoblasts are fewer in
number and less myogenic than those from healthy hu-
man muscle [51,52] and poor proliferation in vitro is
widely interpreted as evidence of their failure as a causal
feature of the pathogenesis [53-59]. At the same time,
counts of satellite cells in situ have indicated that they
are more frequent in DMD than in normal muscle
[60-62]. But our ability to investigate the undoubted
in vivo regeneration deficit in DMD by comparison with
normal human muscle is limited by available technology.
The discrepancy between the effective regeneration in
the mdx mouse and its progressive failure in DMD has
prompted the breeding of a telomerase-null mutation
onto the mdx background, aiming to limit the supply of
stem cells [63]. But the more general disruptive influ-
ence of telomere abnormalities on gene expression, in
addition to their effects on cell proliferation, complicates
interpretation of data from this animal.
Role of fibre branching in mdx hypertrophy
Since mean fibre diameter does not differ significantly
between mdx and WT [16,21,64,65], hypertrophy is
commonly assumed to reflect an increase in fibre num-
bers, although in histological sections, it is difficult to
distinguish fibre number from fibre branching [18,19,66]
and branching itself has recently been shown to be the
main component of mdx muscle hypertrophy [19]. Thus,
the hypertrophy in the mdx mouse involves two sep-
arate elements: a large increase in the number of
myonuclei per fibre and extensive fibre branching
that appears to arise from aberrant patterns of myoblast
fusion [18,19,67,68].Interestingly, branching has also been linked to sus-
ceptibility of fibres to work-induced damage [69-71],
raising the interesting and unresolved question of why
the most active degeneration occurs at a time before
branches are detected while older muscles, with exten-
sive fibre branching, show relatively little active path-
ology [16,21].
Central nucleation equates with hypernucleation
We were surprised to find that the strings of closely ad-
jacent, non-juxta-sarcolemmal, ‘central nuclei’ effectively
accounted for all of the hypernucleation in mdx muscle
fibres. Although the number of peripheral nuclei per
fibre remains constant, the excess being centrally lo-
cated, BrdU marking shows that myonuclei in both posi-
tions are renewed during regeneration. The status of
central nuclei, whether as an accommodation to the high
rates of protein turnover in dystrophic muscle [15,26] or
a fundamental defect in control of myonuclear number
and placement, remains to be determined. Are they con-
tributors to the myopathic process or a result of it [72]?
In any event, it has implications for gene and exon-
skipping therapies that are targeted at myonuclei. If
these supernumerary myonuclei are transcriptionally ac-
tive, they represent extra targets for such therapeutic
agents; if not, they may act as counter-productive de-
coys. In non-rodent species, persistent central nucle-
ation is not a conspicuous feature and hypernucleation
has not been specifically investigated in muscular
dystrophies.
It has been noted that there is a general inverse rela-
tionship between myonuclear domain and force produc-
tion [73] that is contravened in mdx muscle, where a
halving of myonuclear domain compared with WT is as-
sociated with a low specific force [14] adding to the idea
that central positioning may reflect a disturbance of nor-
mal nuclear/sarcoplasmic relationships. The question of
whether DMD and GRMD muscles have high myonuc-
lear densities and whether the persistent central nucle-
ation seen in adult WT mouse muscle after regeneration
[20] is clearly of interest in this regard [74,75].
Conclusions
Observations
1. We have analysed the growth, loss and regeneration
of skeletal muscle in the mdx mouse by comparison
with the WT mouse.
2. From birth up to the onset of the myopathy,
mdx mouse muscle grows at the same rate as
WT mouse muscle but lags behind it in absolute
size, with fewer myonuclei and smaller myonuclear
domains than WT and contain excess lysosomal
structures.
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the young pre-myopathic mdx mouse than those of
the age-matched WT.
4. After onset of the myopathy, mdx muscles become
hypertrophic and hypernucleated but the myonuclear
domain shrinks to half of the WT size.
5. During the myopathic phase, mdx muscle fibres
become increasingly branched and accumulate
strings of myonuclei that are centrally positioned
within the fibres.
6. These central nuclei account entirely for
supernumerary myonuclei in mdx; the number of
peripheral nuclei per fibre remains constant.
7. The number of satellite cells per fibre increases
progressively in the mdx mouse, but the number per
myonucleus remains constant and does not differ
from that of the WT.
8. We describe two BrdU labelling protocols to permit
quantitative comparison of muscle turnover in the
mdx mouse.
Interpretations
Our data show no compromise of regeneration in limb
muscles of the mdx mouse. Neither satellite cell number
nor proliferative capacity is a limiting factor in the main-
tenance of muscle size and structure in this animal. We
suggest that attention to defects in regenerative mecha-
nisms in the mdx dystrophy are, as in aging muscle [42],
subject to too strong a focus. This distracts from those
aspects of the mdx myopathy that do closely simulate
DMD pathology, such as defects in myofibre stability,
where translation of findings from mouse to man is
more likely to be of immediate practical value. A more
detailed comparison of the cellular and molecular events
that are common to DMD and mdx pathologies, or pe-
culiar to one or the other, should also prove rewarding
in this respect [7,32].
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